According to the fact that the efficacy of cancer vaccines may require more time to be demonstrated in breast cancer patients due to late-occurring recurrences, the extended follow-up data of this phase II trial collected after 55 months demonstrated statistically significant DFS improvement in TNBC patients and patients with a stage IIB/III disease and low HER2 expression [31]. The gene discussed is ERBB2; the disease is cancer.